化疗联合靶向药物治疗仅肝转移结直肠癌的转化策略:系统综述
该系统综述纳入2008年后发表的20项II/III期随机试验,评估不可切除结直肠癌仅肝转移(CRLM)患者一线全身转化治疗。研究发现试验间在不可切除标准、预后/预测因素(如RAS/BRAF突变状态)及终点报告上高度异质,CRLM患者R0切除率在22-57%之间,无法从现有数据中选出最优转化方案。
要点
- CRLM患者R0切除率在CRLM专项研究中为22-57%,在mCRC研究亚组中为11-38%。
- 研究人群和设计异质性阻碍跨研究比较,无法确定最优转化方案。
核心结论
- 由于研究人群、试验设计、RAS/BRAF突变状态使用及不可切除标准差异/缺失,跨研究比较受阻,无法从现有数据中选出最优转化全身方案。
研究设计与样本
- 系统综述纳入2008年后发表的II/III期随机试验,共20项:7项为不可切除CRLM患者的前瞻性研究,13项为不可切除mCRC总体人群研究并对CRLM患者进行回顾性亚组分析。
主要发现
- 试验和研究人群在预后/预测因素、主要终点使用及长期临床结局报告方面存在异质性。
- CRLM患者的R0切除率在CRLM专项研究中为22-57%,在mCRC研究亚组中为11-38%。
关键数值与推荐
- CRLM专项研究中R0切除率为22-57%。
- mCRC研究亚组中CRLM患者R0切除率为11-38%。
临床怎么用
- 临床解读转化治疗试验时需注意不可切除标准、RAS/BRAF状态及研究人群异质性,不能直接跨研究比较方案优劣。
局限性
- 纳入试验在不可切除标准、预后/预测因素及终点报告上存在异质性,且多数未提供基线不可切除标准。
- 13项mCRC研究对CRLM患者仅为回顾性亚组分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is no consensus on the optimal systemic conversion therapy in patients with unresectable colorectal cancer liver-only metastases (CRLM) to achieve a complete resection. Interpretation of trials is complicated by heterogeneity of patients caused by emerging prognostic and predictive characteristics, such as RAS/BRAF mutation status, lack of consensus on unresectability criteria and lack of data on clinical outcome of secondary resections. A systematic review was performed of characteristics of study populations and methodology of trials regarding patients with initially unresectable colorectal cancer liver-only metastases. METHODS: Phase II/III randomised trials, published after 2008, regarding first-line systemic conversion therapy in patients or subgroups of patients with CRLM were included. Data on secondary resection outcomes were collected. RESULTS: Overall, 20 trials were included for analysis: seven prospective trials in patients with unresectable CRLM and 13 trials in the overall population of unresectable metastatic colorectal cancer (mCRC) with retrospective subgroup analysis of CRLM patients. Fourteen trials did not provide unresectability criteria at baseline, and criteria differed among the remaining studies. Trials and study populations were heterogeneous in prognostic/predictive factors, use of primary end-points, and reporting on long-term clinical outcomes. R0-resection rates in CRLM patients varied between CRLM studies and mCRC studies, with rates of 22-57% and 11-38%, respectively. CONCLUSIONS: Cross-study comparison of (subgroups of) studies regarding first-line systemic treatment in patients with unresectable CRLM is hampered by heterogeneity in study populations, trial designs, use of (K)RAS/BRAF mutational tumour status, and differences/absence of unresectability criteria. No optimal conversion systemic regimen can be selected from available data. Prospective studies with well-defined criteria of these issues are warranted.
引用
- Bolhuis K, Kos M, van Oijen MGH, et al. Conversion strategies with chemotherapy plus targeted agents for colorectal cancer liver-only metastases: A systematic review. Eur J Cancer. 2020. PMID: 33189037. doi:10.1016/j.ejca.2020.09.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。